This trial is testing olaparib, a PARP inhibitor, as a possible treatment for metastatic castration-resistant prostate cancer. The trial will also study the best dose of olaparib and the side effects of the combination treatment.
2 Primary · 11 Secondary · Reporting Duration: From randomization to PSA progression by Prostate Cancer Working Group (PCWG) 3 criteria, assessed up to 2 years
133 Total Participants · 2 Treatment Groups
Primary Treatment: Olaparib · No Placebo Group · Phase 1 & 2
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: